CYNK-CAR candidates are being developed as allogeneic, off-the-shelf approaches through gene modification of human placental hematopoietic stem cell-derived natural killer (NK) cells. Various CAR constructs against hematological and solid tumor targets are under pre-clinical evaluation.
NK cell activation is governed by the balance of activation and inhibitory signaling. CAR expression on NK cells augments anti-tumor response in one of two ways, by either supplementing tumor recognition in the absence of appropriate activating ligand expression on tumors or tipping the signaling balance in favor of activation when tumor cells express high levels of inhibitory ligands.
Several CAR constructs targeting hematological and solid tumor indications are currently under development.
CAR expression augments tumor recognition and anti-tumor cytotoxicity